Lexaria Bioscience Corp.
LEXX
$1.35
$0.032.27%
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 496.90K | 464.30K | 411.00K | 404.70K | 279.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 496.90K | 464.30K | 411.00K | 404.70K | 279.70K |
| Cost of Revenue | 2.70K | 4.80K | 4.80K | 17.50K | 20.50K |
| Gross Profit | 494.20K | 459.50K | 406.20K | 387.20K | 259.30K |
| SG&A Expenses | 4.00M | 3.79M | 3.07M | 2.64M | 2.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.74M | 6.16M | 4.97M | 5.62M | 6.15M |
| Operating Income | -7.25M | -5.70M | -4.56M | -5.22M | -5.87M |
| Income Before Tax | -7.33M | -5.81M | -4.87M | -5.47M | -6.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.33 | -5.81 | -4.87 | -5.47 | -6.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 10.50K | 13.30K | 21.20K | 30.70K | 40.00K |
| Net Income | -7.32M | -5.80M | -4.85M | -5.44M | -6.09M |
| EBIT | -7.25M | -5.70M | -4.56M | -5.22M | -5.87M |
| EBITDA | -7.17M | -5.62M | -4.43M | -5.07M | -5.72M |
| EPS Basic | -0.49 | -0.46 | -0.47 | -0.71 | -0.87 |
| Normalized Basic EPS | -0.30 | -0.28 | -0.27 | -0.42 | -0.52 |
| EPS Diluted | -0.49 | -0.46 | -0.47 | -0.71 | -0.87 |
| Normalized Diluted EPS | -0.30 | -0.28 | -0.27 | -0.42 | -0.52 |
| Average Basic Shares Outstanding | 57.00M | 49.38M | 41.78M | 34.37M | 29.55M |
| Average Diluted Shares Outstanding | 57.00M | 49.38M | 41.78M | 34.37M | 29.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
